Hyperthermia

Hyperthermia can be caused by fevers and by environmental exposure to heat sources. Maternal temperature increases are transmitted to the fetus. For several decades it has been demonstrated that elevated body temperature can cause malformations in animal studies. There is growing evidence that the same also applies to humans; mild exposure during the pre-implantation period and more severe exposure during embryonic and fetal development often resulL in prenatal death and abortion. Hyperthermia also causes a wide range of structural and functional defects. The central nervous system (CNS) is most at risk, probably because it cannot compensate for the loss of prospective neurons by additional divisions by the surviving neuroblasts, and it remains at risk at stages throughout pre- and postnatal life, although its possible effects at these stages have not been studied in detail (Edwards 2006). There are indications that some malformations, such as neural tube defects (Shaw 1998), but also heart defects, renal anomalies, and gastroschisis, were more frequently observed after prolonged periods of high fever in early pregnancy (e.g. Abe 2003, Chambers 1998). in this prospective study, 115 pregnant women with high fever (38.9° C for 24 hours or more) were compared with 147 women with moderate fever (<38.9° C, or <24 hours) and with women without fever. About 80% of these febrile periods occurred in the first trimester. The relative risk for congenital malformations calculated in this study, however, was not of statistical significance. In a cohort study of 24 040 pregnant women, where 1145 pregnancies resulted in a miscarriage or stillbirth, there was no evidence that fever in the first 16 weeks of pregnancy is associated with fetal death was found (Andersen 2002). In a commentary it was pointed out that the main limitation of this study was that the risk of fetal death before week 6 could not be assessed, and therefore no definite conclusions could be made (Chambers 2006). The question of whether elevated body temperature may be responsible for the so-called "vascular disruption disorders", where developing organs are deprived of sufficient blood supply, is still under discussion (Martínez-Frías 2001, Graham 1998). A rise in body temperature of = 2" C for more than 24 hours is acknowledged nowadays to be associated with an increased risk of developmental defects.

An increased risk from sauna or hot-tub bathing has been discussed (Li 2003, Milunsky 1992), but data are not sufficient for definite conclusions (Chambers 2006, Herz-Picciotto 2003). However, in view of the relatively large volume of animal data and the association between high maternal fever and NTDs, a risk cannot be excluded. In a hot-tub (39-40° C), body temperature (studied in nonpregnant women) may reach 38.9° C after only 10-20 minutes (Harvey 1981). Women of reproductive age and who may be pregnant should limit exposure to hot-tubs to less than 15 minutes in 39° C water and less than 10 minutes in 40° C water (Chambers 2006). Time limits for hot-tubs are shorter than for saunas; the latter permit greater heat loss by evaporation and perspiration. In Finland, where sauna bathing is very common, even during pregnancy, no association with adverse pregnancy outcomes has been detected.

Use of electric blankets or heated waterbeds has not demonstrated any additional risk of congenital malformations to date. The use of birthing pools has raised some concern in a case report (Rosevaer 1993), where, after staying in water of 39° C for several hours, two mothers delivered infants in poor condition; both newborns died shortly afterwards.

Recommendation. When high fever does arise in early pregnancy, paracetamol (acetaminophen) should be taken to lower the body temperature, together if necessary with other measurements such as cool wrappings and sufficient fluid intake. Saunas or hot-tubs should not exceed 10 minutes. In general, sources of possible overheating should be avoided. In cases of high fever episodes in early pregnancy, diagnostic measurements such as detailed fetal ultrasound should be considered.

2.6.57 Traveling

When pregnant patients are traveling long distances, or going abroad, several possible risks should be discussed:

■ Prophylactic measurements to prevent infections (for malaria prophylaxis, see section 2.6.24; for vaccinations, see Chapter 2.7)

■ The risk of other infections (fever, fluid loss), and required therapy

■ In long-distance air travel, cosmic radiation, the increased risk of thrombotic events due to prolonged immobilization, decreased air (oxygen) pressure comparable with an altitude of approximately 2500 m, and physical and psychic stress.

No specific malformations have been associated with established vaccinations or with malaria prophylaxis. However, with some of them there is insufficient experience with use in pregnancy (see Chapter 2.7). It should be pointed out that the increased physical stress associated with long-distance travel in predisposed women might increase their risk for spontaneous abortion. Another risk is of "common" infections, due to altered hygienic standards in the destination country. The accompanying fever, dehydration or other complications may also endanger the fetus.

The quantity of ionizing radiation in air travel will vary according to several conditions, but as far as we know doses will not be high enough to incorporate an additional risk of malformations.

Staying at high altitudes carries the problem of decreased air pressure and the risk of high altitude sickness. Although a decreased birth weight in infants bom to mothers who live at (moderate) high altitudes has been observed, a short-term stay in conditions with moderate decreased air pressure does not seem to carry a risk of fetal hypoxia. Fetal oxygen supply at very high altitudes (>3300 m or 11 000 ft) cannot be guaranteed, and the risk of maternal high altitude sickness may endanger the mother and child. Healthy pregnant women can probably stay at a moderately high altitude for a short period, but avoiding exercise, or maintaining hydration and waiting several days for acclimatization before starting moderate exercise, is recommended (Jean 2005, Rodway 2004, Niermeyer 1999). Heavy exercise with increasing body temperature must be avoided (Samuel 1998). During long-distance flights, air pressure and the oxygen partial pressure are kept to the same level as at an altitude of 2500 m, which carries no risk for healthy (pregnant) individuals.

Recommendation. The need for long journeys, especially to tropical destinations, by pregnant women should be critically evaluated. Women with a history of spontaneous abortion should preferably postpone their journey, Women with risk factors for spontaneous abortion, pre-eclampsia or placental abruption, or whose babies are at risk of intrauterine growth restriction (IUGR), should not go to (very) high altitudes. When a journey has been made during pregnancy without any complications, further diagnostic procedures are not warranted.

References

Abc K, Honein MA, Moore CA. Maternal febrile illnesses, medication use, and the risk of congenital renal anomalies, Birth Def Res A 2003; 67: 911-18.

ACOG Technical Bulletin. Pulmonary Disease in Pregnancy, No. 224. Intl J Gynaecol Obstet 1996; 54: 187-96.

Adam I (A), Elwasila E, Ali DAM et al. Arlemelhcr in the treatment of falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg 2004; 98 509-13.

Adam 1 (B), Elwasila ET, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg 2004; 98: 540-43.

Adam I, Elwasila E, Homeida M. Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. Ann Trop Med Parasitol 2005; 99: 37-40.

Aleck KA, Bartly DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997; 72: 253-6.

Alecrim WD. Espinosa FEM, Alecrim MGC. Plasmodium falciparum infection in the pregnant patient. Infect Dis Clin North Am 2000: 14: 83-95.

Alimenti A, Forbes JC, Oberlander TF et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 2006; 118: 1139-45.

Amado JA. Pesquera C. Gonzalez EM et al. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66: 221-3.

Andersen AMN, Vastrup P. Wohlfahrt J et al. Fever in pregnancy and risk of fetal death: a cohort study. Lancet 2002; 360(9345): 1552-6.

Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry Interim Report for 1 |anuary 1989 through 31 July 2004. Wilmington, NC: Registry Coordinating Center, 2004 (available at www.apregistr.com).

Arnold SR. Degani N, King SM; Retrospective study to characterize the effects of antiretroviral therapy in infants bom to HIV-infected mothers. Pediatr Res 2002; 51(4 Pt2):282A.

Atmar RL, Englund JA. Hammiii H, Complications of measles during pregnancy. Clin Infect Dis 1992; 14: 217-26,

Bar-Oz B. Moretti ME, Bishai R et al. Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am | Obstet Gynecol 2000; 183: 617-20.

Barret B, Tardieu M, Rustin P et al, Persistent mitochondrial dysfunction in IIIV-1-exposed hut uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17. 1769-85.

Beard CM. Noller Kl, O'Fallon WM et al. Cancer after exposure to metronidazole. Mayo Clin Proc 1988; 63: 147-53.

Ben-David S. Einarson T, Ben-David Y et al. The safety of nitrofurantoin during the first trimester of pregnancy; meta-analysis. Fund Clin Pharmacol 1994; 28: 248-51.

Berkovitch M, Patuszak A, Gazarian M et al. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 84: 535-8.

Berkovitch M, Segal-Sochcr t, Greenberg K et al. First trimester exposure to Cefuroxim: a prospective cohort study. Br | Clin Pharmacol 2000; 50: 161-5.

Berkovitch M. Diav-Citrin O, Greenberg R et al. First-trimester exposure to amoxy-cillin/cJavuianic acid: a prospective, controlled study, Br I Clin Pharmacol 2004: 58: 298-302.

Bernard B. Abate M, Thielen PF et al. Maternal-fetal pharmacological activity of amikacin. ] Infect Dis 1977; 135: 925-32.

Berwaerts ). Verhelst J. Mahler C et al. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 1999; 13: 175-82.

Uhargava P. Kuldeep CM, Mathur NK: Antileprosy drugs, pregnancy and fetal outcome. Intl I Lepr Other Mycobact Dis 1996; 64: 457,

Blanche S, Tardieu M, Kustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.

Bothamley G. Drug treatment for tuberculosis during pregnancy - safety considerations. Drug Saf 2001; 24: 553-65.

Bourget P. Fernandez H, Delouis C et al. Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen. ] Clin Pharm Tlier 1991; 16: 167-76. "

Brabin BJ, Eggelte TA. Parise M et al. Dapsone therapy for malaria during pregnancy -maternal and fetal outcomes. Drug Saf 2004; 27: 633-48.

Briggs GG. Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.

Brost BC. Newman RB. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am 1997; 24: 659-73.

Brown ZA, Gardella C, Wald A et al. Genital herpes complicating pregnancy. Obstet Gynecol 2005; 106(4): 845-56.

Bruel H, Guillcmant V, Satadin TC et al. Anémie hémolytique chez un nouveau - né après prise maternelle de nitrofurantoine en fin de grossesse. Arch Pédiatr 2000; 7; 745-7.

Brumfitt W. Pursell R. Trimethoprim sulfamethoxazole in the treatment ofbacteriuria in women. I Infect Dis 1973; 128: S657-63.

Burtin P. Taddio A. Ariburno O el al. Safely of metronidazole in pregnancy: a metaanalysis. Am J Obstet Gynecol 1995; 172: 525-9.

Caro Paton T. Carvajal A. Martin de Diego I et al. Is metronidazole teratogenic? A meta-analysis. Br ) Clin Pharmacol 1997; 44(2): 179-82.

Chamberlain A. White S. Bawdon R et al. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am | Obstet Gynecol 1993; 168: 667-73.

Chambers CD. lohnson KA. Dick LM et al. Maternal fever and birth outcome: a prospective study. Teratology 1998; 58: 251-7.

Chambers CD. Kisks of hyperthermia associated with hot tub or spa use by pregnant women. Birth Def Res A 2006; 76; 569-73.

Choi JS, Han |Y. Ahn HK. Fetal outcome after exposure to antihelminthics albendazole and flubendazole during early pregnancy. Birth Def Res A 2005: 73: 349.

Cooper WO, Ray WA, Griffin MR. Prenatal description of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol 2002; 100: 101-6.

Covington Dl. (A), Tilson H, Flder ( et al. Assessing teratogenicity of antiretroviral drugs monitoring and analysis plan of the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 2004; 13: 537-45.

Covington DL (B), Conner SD. Doi PA el al. Risk of birth defects associated with nel-finavir exposure during pregnancy. Obstet Gynecol 2004; 103: 1181-9.

Culnane M, Fowler MC. Lee SS et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. J Am Med Assoc 1999:281: 151-7.

Czeizel AF.. A case-control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 1990; 4: 305-13.

Czeizel AE, Rockenbauer M. Teratogenic study ofdoxycycline. Obstet Gynecol 1997; 89: 524-8.

Czeizel AE, Rockenbauer M. Olsen |. Use of antihiotics during pregnancy. Eur | Obstet Gynecol 1998:81: t-8.

Czeizel AE, Rockenbauer M, Sorensen MT et al. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicof 1999; 13: 531-6.

Czeizel AE (A). Rockenbauer M. Olsen ) et al. Oral Phenoxymethylpenicillin treat ment during pregnancy. Results of a population-based Hungarian case-control study. Arch Gynecol Obstet 2000; 263: 178-81.

Czeizel AE (B), Rockenbauer M. Sorensen HT, Olsen |. A teratological study of lin-cosamides. Scand J Infect Dis 2000: 32: 579-80.

Czeizel AE (C), Rockenbauer M. A population-based case-control study of oral Oxytetracycline treatment during pregnancy. Eur [ Obstet Gynecol Reprod Biol 2000; 88: 27-33.

Czeizel AE (A). Rockenbauer M. Sorensen HTet al. A population-based case-control teratologic study of ampicillin treatment during pregnancy. Am ] Obstet Gynecol 2001; 185: 140-7.

Czeizel AE (B), Rockenbauer M, Sorensen HT et al. Use of cephalosporins during pregnancy and in the presence of congenital malformations. A population-based case-control study. Am ] Obstet Gynecol 2001: 184: 1289-96.

Czeizel AE (C), Rockenbauer M, Sorensen HT et al Augmentin treatment during pregnancy and the prevalence of congenital malformations. A population-based case-control teratologic study. F.ur | Obstet Gynecol 2001; 97: 188-92.

Czeizel AE (A), Kaüy Z. Vargha P. A population-based case-control teratological study of vaginal econazole treatment during pregnancy. F.ur | Obstet Gyn Reprod Biol 2003: 111: 135-40.

Czeizel AE (B), Kazy Z, Vargha P. A casc-control teratological study of vaginal natamycin treatment during pregnancy. Reprod Toxicol 2003: 17: 387-91.

Czeizel AF^ (A). Fladung B, Vargha P. Preterm birth reduction after clotrimazole treatment during pregnancy. European ] Obstet Gyn Reprod Biol 2004; 116: 157-63.

Czeizel AE (B). Kazy Z. Puho E. Population-based case-control teratologic study of topical miconazole. Congenital Anomalies 2004; 44: 41-5.

Davidson PT, Managing tuberculosis during pregnancy. Lancet 1995; 346: 199-200.

Dean JL, Wolf )E, Rancini AC el al. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18: 364-8.

Deen JL. von Seidlein L. Pinder M el al. The safety of Ihe combination artesunate and pyrimcthamine-sulfadoxinc given during prcgnancy. Trans R Soc Trop Med Hyg 2001:95:424-8.

Dencker BB. Larsen H, Jensen ES el al. Birth outcome of 1886 pregnancies after exposure to Phenoxymethylpenicillin in utero. Clin Microbiol Infect 2002: 8: 196-201.

De Santis M, Carducci B, de Santis L et al. Periconceptional exposure <0 efavirenz and neural tube defects. Arch Intern Med 2002; 162(3): 355.

De Silva NR. Sirisena JLGj, Gunasekera DPS et al. Effect of mebendazole therapy during pregnancy on birth outcome. Lancet 1999; 353: 1145-9.

Diav-Citrin O, Gotteiner T, Shechtman S et al. Pregnancy outcome following gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 2001; 63: 186-92.

Diav-Citrin O, Shechtman S, Arnon J. Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study. Am ] Obstet Gynecol 2003; 188: 282-5.

Dobias L. Cerna M. Rössner P et al. Genotoxicity and carcinogenicity of metronidazole. Mutation Res 1994; 317: 177-94.

Donders GG. Treatment of sexually transmitted bacterial diseases in pregnant women. Drugs 2000. 59(3): 477-85-

Drinkard CR, Shatin D. Clouse |. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 200Ü; 9: 549-56.

Edwards M], Shiota K. Smith MSR et al. Hyperthermia and birth defects. Reprod Toxicol 1995; 9: 411.

Edwards M|. Review: Hyperthermia and fever during pregnancy, Birth Def Res Part A 2006; 76: 507-16.

Einarson A. Philips E, Mawji F et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatal 1998; 9: 523-5.

Ely EW, Peacock JE |r, Haponik EF et al Cryptococcal pneumonia complicating pregnancy. Medicine Baltimore 1998; 77: 153-67.

Espinal MA, Reingold AL, Lavandera M. Effect of pregnancy on Ihe risk of developing active tuberculosis {see comments). | Infect Dis 1996; 173(2): 488-91.

Fowler MG. Follow-up of children exposed to perinatal antiretrovirals. Teratology 2000; 61: 395-6.

Frenkcl LM, Brown ZA, Bryson Y| et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am | Obstet Gynecol 1991; 164: 569-76.

Frieden TR, Sterling TR, Munsiff SS et al. Tuberculosis. Lancet 2003; 362: 887-99.

Gail |E. Hemolytic reactions to nitrofurantoin in patients with glucose-6-phosphate dehydrogenase deficiency: theory and practice. DICP 1990; 24: 1210-13.

Garratty G, Leger RM, Arndt PA. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am j Obslel Gynecol 1999; 181: 103-4.

Giamarellou H, Kolokythas, Petrikkos G et al. Pharmacokinetics of three newer quinolones in pregnant and iactating women. Am J Med 1989; 87(Suppl 5A): S49-51.

Graham |M, Edwards MJ, Edwards MJ. Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans. Teratology 1998; 58: 209-21.

Gyapong [O. Chinbuah MA. Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic Filariasis. Trop Med Intl Health 2003; 8: 1093-101.

Hanson IC, Antonelli TA, Sperling HS et al. Lack of tumors in infants wilh perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acq Immune Defic Syndr Hum Ketrovirol 15«; 20: 463-7.

Hart CW. Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol 1964;80:407-12.

Harvey MAS. McRorie MM. Smith DW. Suggested limits to the use of hot tubs and sauna by pregnant women. Can Med Assoc J 1981: 125: 50-54.

Heikkilä A, Erkkola R, Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokin 1994: 27: 49-62.

Heikkinen T. Laine K. Neuvonen PJ et al The transplacental transfer of the macrolidc antibiotics erythromycin, roxithromycin and azithromycin. Br ) Obstet Gynaecol 2000; 107: 770-75,

Hernandez-Diaz S, Werler MM. Walker AM et al. Folic acid antagonists during pregnancy and the risk of birth defects, N Engl J Med 2000; 343; 1608-14

Hemandcz-Diaz S, Werler MM, Walker AM et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153: 961-8

Herz-Picciotto I, Howards PP. Invited commentary: hot tubs and miscarriage -methodological and substantiveb reasons why the case is weak. Am ) Epidemiol 2003; 158: 938-40.

Hill |, Roberts S, Herpes simplex virus in pregnancy: new concepts in prevention and management. Clin Perinatol 2005; 32(3): 657-70.

Hill LM, Fetal distress secondary to vancomycin-induced maternal hypotension. Am 1 Obstet Gynecol 1985; 153 : 74-5.

Hitti J. Frenkel LM, Stek AM et al. Maternal toxicity with continuous nevirapine in pregnancy - results from PACTG 1022. |AIDs 2004: 36(3): 772-6.

Hulton S-A, Kaplan BS. Renal dysplasia associated with in utero exposure to gen-tamycin and corticosteroids. Am J Med Genet 1995; 58: 91-3.

Inman W, Pearce G. Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, wilh special reference to the outcome of pregnancy. Eur ( Clin Pharmacol 1994; 46: 115-18.

Jensen P, Skriver MV, Floyd A et al. A population-based study of maternal use of amoxycillin and pregnancy outcome in Denmark. Br) Clin Pharmacol 2003; 55: 216-21.

Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999; 19:221-2.

Jin ZK, Effects of gentamycin on the fetal kidneys. Chinese J Obstet Gynecol 1992; 27: 157-8.

loesoef MR. Schmid GP, Hillier SL. Bacteria! vaginosis: a review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999: 28(Suppl 1): S57-65.

Källdn B, Ollerblad AJ. Olausson P. Danielsson BR, Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20: 209-14.

Kazy Z, Puho E, Czeizel AE. Parenteral polymyxin B treatment during pregnancy. Reprod Toxicol 2005; 20: 181-2.

King CT. Rogers PD, Geary [D et al. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27(5): 1151-60.

Kinzy BJ. Taylor [W. Trimethoprim and folinic acid. Ann Intern Med 1984: 101: 565.

Knudsen LB. No association between griscofulvin and conjoined twinning. Lancct 1987; 2: 1097.

Laibl VR, Sheffield JS. Tuberculosis in pregnancy. Clin Perinatol 2005; 32: 739-47.

Larscn B. Glover DD. Serum erythromycin levels in pregnancy. Clin Therapeut 1998; 20: 971-7.

Larsen H, Nielsen GL, Sorensen HT et a!. A follow-up study of birth outcome in users of pivampicillin during pregnancy. Acta Obstet Gynecol Scand 2000; 79: 379-85.

Larsen H. Nielsen GL. Schonheyder HC et al. Birth outcome following maternal use of fluoroquinolones. Intl J Antimicrob Agents 2001; 18: 259-62.

Lewis JH Drug hepatotoxicity in pregnancy. Eur ) Gastroenterol Hepatol 1991; 3: 883-91.

Li DK, janevlc T. Odouli R et al. Hot tub use during pregnancy and the risk of miscarriage. Am ] Epidemiol 2003; 158: 931-7.

Lipshultz SE, Easley KA. Orav J et al. Absence of cardiac toxicity of zidovudine in infants. N Engl | Med 2000; 343: 759-66.

Loebstem R, Acidis A. Ho E et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998: 42: 1336-9

Lopcz-Rangel E, Van Allen ML Prenatal exposure to fluconazole: an identifiable dys morphic phenotype. Birth Def Res A 2004; 70: 261.

Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloris stenosis. Am | Obstet Gynecol 2002; 186: 288-90,

Mallie |P, Coulon G. Billerey C et al. In utcro aniinoglycosides-induced nephrotoxic ity in rat neonates. Kidney Intl 1988; 33: 36-44.

Mandelbrot L. Landreau-Mascaro A, Rekacewicz C et al. Lamivudine-zidovudme combination for prevention of maternal-infant transmission of HIV-1. f Am Med Assoc 2001; 285: 2083-93.

Manka W. Solowiow R, Okrzeju D. Assessment of infant development during an 18-month follow-up after treatment of infections in pregnant women with cefurox-ime axetil. Drug Saf 2000; 22: 83-8

Mantovani A, Macri C, Stazi AV et al. Tobramycin-induced changes in renal histology of fetal and newborn Sprague-Dawley rats. Teratog Carcinog Mutagen 1992: 12: 19-50.

Martin CL. Update on the teratogenicity of efavirenz. AIDS Rev 2005; 7: 246.

Martfnez-Frfas ML, Mazario M)G, C'aldas CFet al. High maternal fever during gestation and severe congenital limb disruptions. Am J Med Genet 2001: 98: 201-3.

Mastroiacovo P, Mazzone T, Botto LD el al. Prospective assessment of prcgnancy outcomes after first trimester exposure to fluconazole. Am J Obstet Gynaecol 1996; 175: 1645-50.

McCormack WM, George H, Donner A et al. Hepatotoxicity of erythromycin estolale during pregnancy. Antimicrob Agents Chemother 1977; 12: 630-35.

McGready R. Clio T, Clio )J et al. Artcmisinin derivates in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 1998; 92: 430-3.

McGready R (A), Clio T, Samuel L et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in prcgnancy. Trans R Soc Trop Med Hyg 2001; 95: 651-6.

McGready R (B), Cho T, Keo NK et al. Artcmisinin antimalarials in prcgnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis2001; 33: 2009-16.

McGready R, Thwai KL, Cho T et al. The effects of quinine and chloroquine antimalarial treatments in (he first trimester of pregnancy. Trans R Soc Trop Med Hyg 2002; 96: 180-84.

McGready R. Ashley EA, Moo E el al. A randomized comparison of artesunate-atovaquone-proguani! versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. ] Infect Dis 2005; 192: 846-53.

Metneki J, Czeizel A. Griseofulvin teratology. Lancet 1987; 1: 1042.

Milunsky A, Ulcickas M, Rothman K] et a!. Maternal heat exposure and neural tube defects. | Am Med Assoc 1992; 268: 882-5.

Mitchell TF, Pearlman MD, Chapman RL et al. Maternal and transplacental pharma cokinetics of cefazolin. Obstet Gynecol 2001; 98: 1075-9.

Mofenson LM (A). Prenatal exposure to zidovudine - benefits and risks. N Engl | Med 2000; 343: 803-5.

Mofenson LM (B). Mclntyre JA. Advances and researches in the prevention of mother-to-child HIV 1 transmission. Lancet 2000; 355: 2237-44.

Morris AAM, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999; 354: 1046-7.

Morris AB. IJobles AR, Cu-Uvin S et al. Protease inhibitor use in 233 pregnancies. J Acq Immune Deik Synd 2005; 40: 30-33.

Myle5 TD, Elam G, Park-Hwang E et al. The |arisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis. Obstet Gynecol 1998; 92: 859-64.

Na Bangehang K, Manyando C, Ruengweerayut R et al. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncompli cated falciparum malaria in third-trimester pregnant women. Eur ) Clin Pharmacol 2005; 61: 573-82.

Newman RD, Parise ME. Slutsker L et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium faIciparuw - e n d e ill i c sub-Saharan Africa. Trop Med Intl Health 2003; 8: 488-506.

Noslen F. Vincenti M, Simpson J et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999; 28: 808-15.

Olds GR. Administration of Praziquantel to pregnant and lactating women. Acta Trop 2003; 86: 185-95.

Paparone PW. Menghetti RA, Case report: neuro-cysticercosis in pregnancy. N) Med 1996; 93: 91-4.

Parke AL. Rothfield NF, Antimalarial drugs in pregnancy - the North American experience. Lupus 1996; 5(Suppl I): S67-9.

Peled Y, Friedman S, Hod M et al. Ofloxacin during the second trimester of pregnancy. D1CP 1991; 25: 1181-2.

Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 1999; 67: 758-9

Philips-Howard PA. Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf 1996; 14: 131-45.

Philips-Howard PA. Steffen R. Kerr 1 el al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. ] Travel Med 1998; 5: 121-6.

Piper JM, Mitchell EF. Ray WA. Prenatal use of metronidazole and birth defects. Obstet Gynecol 1993; 82: 348-52.

Pursley TJ. Blomquist IK, Abraham J et al. Fluconazole-induced congenital anomalies in three infants. CID 1996; 22: 336-40.

Raju B. Schluger NW. Tuberculosis and pregnancy. Sem Respir Crit Care Med 1998: 19: 295-306.

Ramsey PS, Vaulcs MB. Vasdev GM et al. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 2003; 188: 714-18.

RCOG (Royal College of Obstetricians and Gynaecologists). Smith JR, Cowan FM, Munday P. The management of herpes simplex infection in pregnancy. Br J Obstet Gynaecol 1998; 105: 255-60,

Reeves DS. Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamoi: a review, Infection 1992; 20{Suppl 4): S313-16.

Reuvers-Lodewijks WF.. F.NTIS - study on anthelmintics during pregnancy. Presentation on the 10th Annual Meeting of the European Network of Teratology Information Services 1999, Madrid.

Reyes MP, Ostrea EM. Cabinian AE et al. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am | Obstet Gynecol 1989; 161: 977-81.

Rezvani M. Koren G, Pregnancy outcome after exposure to injectable ribavirin during embryogenesis. Kcprud Toxicol 2006; 21: 113-15.

Rosa F, Hernandez C. Carlo WA. Griseofutvin teratology, including two thoracopagus conjoined twins. Lancet 1987; I: 171.

Rosa F. Amantadine pregnancy experience. Reprod Toxicol 1994; 8: 531.

Rosevear SK, Fox R, Marlow N et al. Birthing pools and the fetus. Lancet 1993; 342: 1048-9,

Samuel BU. Barry M. The pregnant traveler. Infect Dis Clin North Am 1998; 12: 325-54.

Sanchez JM. Moya G Fluconazole teratogenicity. Prenat Diagn 1998; 18: 862-9.

Sanchez-Sainz-Trapaga C, Gutierrcz-Fonseca R, Ibanez-Ruiz C et al. Relationship between a case of severe hearing loss and use of gentamycin in the pregnant mother. An Esp Pediatr 1998; 49: 397-8.

Sarkar MS. Rowland K, Koren G, Pregnancy outcome following gestational exposure to terbinafine: a prospective comparative study. Birth Def Res A Clin Mol Teratol 2003: 67: 390.

Savioli L, Crompton DW, Ncira M. Use of anthelmintic drugs during pregnancy. Am J Obstet Gynecol 2003; 188: 5-6.

Schaefer C, Amoura-Elefant E, Vial T et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a Case Registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Keprod Biol 1996; 69: 83-9.

Schick B. Horn M. Librizzi R et al. Pregnancy outcome following exposure to clarithromycin. Reprod Toxicol 1996; 10: 162.

Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J Travel Med 1999; 6(2): 22-33.

Scott LL. Prevention of perinatal herpes: prophylactic antiviral therapy? Clin Obstet Gynecol 1999; 42(1): 134-48.

Shaw GM.Todoroff. Velie EM et al. Maternal illness, including fever, and medication use as risk factors for neural tube defects. Teratology 1998; 57: 1-7.

Shephard TH. Brent RL, Friedman |M et al. Update on new developments in the study of human teratogens. Teratology 2002; 65: 153-61

Shin S, Guerra D, Rich M et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis 2003; 36: 996-1003.

Shulman CE. Dorman EK. Reducing childhood mortality in poor countries; importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg 2003; 97: 30-35.

Sobel ID. Use of antifungal drugs in pregnancy - a focus on safety. Drug Saf 2000: 23: 77-85.

Sorensen HT, Nielsen Gl, Olesen et al. Risk of malformation and other outcomes in children exposed to fluconazole in utero. Br j Clin Pharmacol 1999: 48: 234-8.

Stein GE. Single-dose treatment of acute cystitis with fosfomycin tromethamine. Ann Pharmacother 1998: 32: 215-17.

Stone KM. Reiff ER, White AD et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the International Acyclovir Pregnancy Registry, 1984-1999. Birth Def Res A 2004; 70: 201-7.

Tagbor H, Bruce J, Browne E et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethaminc used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet 2006; 368: 1349-56

Thapa PB, Whitlock |A, Brockman-Worrell KG et al. Prenatal exposure to metronidazole and risk of childhood cancer; a retrospective cohort study of children younger than 5 years. Cancer 1998; 83(7): 1461-8.

Thomas F, Erhart A, D'Alessandro I). Can amodiaquine be used safely during pregnancy? Lancet Infect Dis 2004; 4(4): 235-9.

Trexler MF, Fräser TG, ¡ones MP. Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream. Am ) Gastroenterology 1997; 92: 2112-13.

Tripathy SN, Tripathy SN. Tuberculosis and pregnancy, Intl J Gynaecol Obstet 2003; 80: 247-53.

Vial T, ENT1S Study on Conazole Antimycotics During Pregnancy. Personal communication, 2001.

Wallon M, Liou C, Garner P et al. Congenital toxoplasmosis: systemic review of evidence of efficacy of treatment in pregnancy. Br Med ) 1999; 318: 1511-14.

Watts DI I. Brown ZA, Money D et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery, Am J Obstet Gynecol 2003; 188: 836-43.

Whitley li. Neonatal herpes simplex virus infection. Curr Opin Infect Dis 2004: 17: 243-6.

WHO (A). Drug Information. Mefloquine: an update on safety issues. Reports on individual drugs 1996; 10: 58-60

WHO (B). World Health Report 1996: Fighting Disease, Fostering Development. WHO 1996:43.

WHO. Assessment of the Safety of Artemisinin Compounds in Pregnancy. Report of two informal consultations convened by WHO ill 2002. WHO/CDS/MAL/2003.1094 and WHO/RBM/TDK/Artemisinin/O3.1.

WHO (A). International Travel and Health Publication 2005; Malaria (http: //whqlib doc. who.int/publications/2005/9241580364_chap7.pdf).

WHO (B). Malaria Control Today. Current WHO Recommendations. Working document, March 2005 (http: //www.who.int/malaria/docs/MCT_workingpaper.pdf).

Witt KL, Cunningham CK. Patterson KB et al. Elevated frequencies of micronucle-atcd erthroyctes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV, Environ Mol Mutagen 2007; 48: 322-9.

Wogclius P, Norgaard M, Gislum M et al. Further analysts of the risk of adverse birth outcome after maternal use of fluoroquinolones. Intl J Antimicrobial Agents 2005; 26: 323-6.

Yaris F, Kesim M. Kadioglu M et al, Gentamicin use in pregnancy. A renal anomaly. Saudi Med J 2004: 25: 958-9.

Yudin MH, Bacterial vaginosis in pregnancy: diagnosis, screening, and management. Clin Perinatal 2005; 32: 617-27.

Zaske DE. Cipolle R], Strate RG et al. Rapid gentamycin elimination in obstetric patients. Obstet Gynecol 1980; 56: 559-64.

Was this article helpful?

0 0
New Mothers Guide to Breast Feeding

New Mothers Guide to Breast Feeding

For many years, scientists have been playing out the ingredients that make breast milk the perfect food for babies. They've discovered to day over 200 close compounds to fight infection, help the immune system mature, aid in digestion, and support brain growth - nature made properties that science simply cannot copy. The important long term benefits of breast feeding include reduced risk of asthma, allergies, obesity, and some forms of childhood cancer. The more that scientists continue to learn, the better breast milk looks.

Get My Free Ebook


Post a comment